Reasons for Donald Denkhaus’s Share Buy of Catalyst Pharmaceuticals, Inc. (CPRX)’s Stock; LE MARE GOLD ORDINARY SHARES (SLLTF) Shorts Increased By 612.5%

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Logo

LE MARE GOLD CORP ORDINARY SHARES (OTCMKTS:SLLTF) had an increase of 612.5% in short interest. SLLTF’s SI was 5,700 shares in June as released by FINRA. Its up 612.5% from 800 shares previously. With 6,600 avg volume, 1 days are for LE MARE GOLD CORP ORDINARY SHARES (OTCMKTS:SLLTF)’s short sellers to cover SLLTF’s short positions. The SI to LE MARE GOLD CORP ORDINARY SHARES’s float is 0.1%. It closed at $0.072 lastly. It is down 0.00% since June 11, 2017 and is . It has underperformed by 12.57% the S&P500.

Le Mare Gold Corp., a resource exploration company, engages in the acquisition and exploration of mineral properties in Canada. The company has market cap of $797,522. It has an option to earn 80% interest in the Cruz Property located in the Pocitos Salar Basin in Salta Province, Argentina; and a 100% interest in the East Fault Property located in Clayton Valley, Nevada, the United States. It currently has negative earnings. The firm was formerly known as Southern Lithium Corp. and changed its name to Le Mare Gold Corp. in February 2018.

More news for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) were recently published by: Seekingalpha.com, which released: “Catalyst Pharmaceuticals Ready To Jump As FDA Accepts The NDA” on June 08, 2018. Seekingalpha.com‘s article titled: “Your Daily Pharma Scoop: 4 NDAs. CPRX, EXEL, ALPMY, ACOR” and published on May 31, 2018 is yet another important article.

The director of Catalyst Pharmaceuticals Inc, Donald Denkhaus, has just obtained – 20,000 shares of the corporation he’s managing – coming to a total trade of $68,200 USD (this based on avg. share price of $3.4). This is not his first insider trade, in the last 30 days, he obtained another 20,000 shares worth $75,000 USD. At the moment, he has ownership of 140,000 shares or 0.14% of the company’s total market cap (Market Capitalization is a measurement of business value based on share price and number of shares outstanding). The public document was revealed on June 11, 2018 with the SEC and is now ready for you here.

Analysts await Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to report earnings on August, 8. They expect $-0.07 EPS, down 40.00% or $0.02 from last year’s $-0.05 per share. After $-0.06 actual EPS reported by Catalyst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 16.67% negative EPS growth.

Investors sentiment decreased to 1.84 in 2018 Q1. Its down 0.13, from 1.97 in 2017Q4. It worsened, as 16 investors sold Catalyst Pharmaceuticals, Inc. shares while 16 reduced holdings. 20 funds opened positions while 39 raised stakes. 53.38 million shares or 3.39% less from 55.25 million shares in 2017Q4 were reported. Stratos Wealth Partners accumulated 1,500 shares or 0% of the stock. Cubist Systematic Strategies holds 0% or 12,835 shares in its portfolio. Element Capital Limited Liability Corporation reported 10,843 shares. Hightower Advsr Ltd Liability Corp has 11,411 shares for 0% of their portfolio. Clear Harbor Asset owns 11,300 shares or 0.01% of their US portfolio. Art Advisors Lc, New York-based fund reported 109,954 shares. Raymond James Fincl Serv Advsrs reported 0% stake. California Employees Retirement Systems holds 0% or 41,332 shares. Strs Ohio holds 223,100 shares. Renaissance Techs Lc owns 1.39 million shares. Citigroup stated it has 39,130 shares. Jpmorgan Chase stated it has 1.15 million shares. Consonance Capital Limited Partnership owns 1.09% invested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) for 4.99M shares. State Bank Of America Corp De holds 0% or 44,126 shares. Tower Ltd (Trc) holds 0% or 3,198 shares.

Among 5 analysts covering Catalyst Pharmaceuticals (NASDAQ:CPRX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Pharmaceuticals has $8.0 highest and $4 lowest target. $5.75’s average target is 70.12% above currents $3.38 stock price. Catalyst Pharmaceuticals had 16 analyst reports since April 26, 2016 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, March 15 report. H.C. Wainwright maintained the shares of CPRX in report on Wednesday, May 30 with “Buy” rating. The firm has “Buy” rating given on Wednesday, November 1 by Roth Capital. The rating was maintained by Piper Jaffray on Monday, August 7 with “Buy”. The firm has “Buy” rating given on Friday, May 11 by H.C. Wainwright. The rating was upgraded by Piper Jaffray on Wednesday, October 5 to “Overweight”. H.C. Wainwright maintained Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) rating on Friday, November 10. H.C. Wainwright has “Buy” rating and $6.0 target. The firm has “Neutral” rating given on Tuesday, April 26 by Piper Jaffray. The firm earned “Overweight” rating on Wednesday, October 5 by PiperJaffray. Roth Capital maintained it with “Buy” rating and $4.75 target in Wednesday, August 30 report.

The stock increased 0.90% or $0.03 during the last trading session, reaching $3.38. About 533,883 shares traded. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has risen 50.23% since June 11, 2017 and is uptrending. It has outperformed by 37.66% the S&P500. Some Historical CPRX News: ; 29/05/2018 – Catalyst Pharmaceuticals Announces FDA Acceptance of NDA and Priority Review Status for Firdapse® (Amifampridine Phosphate) fo; 29/05/2018 – CATALYST PHARMACEUTICALS REPORTS FDA ACCEPTANCE OF NDA &; 29/03/2018 – Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse(R) for Treatment of Lambert-Eaton Myasthenic Syndrome; 08/03/2018 Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results Conference Call and Webcast on Thursday, March 1; 19/04/2018 – CATALYST PHARMA: FIRST PATIENT ENROLLED IN FIRDAPSE PHASE 3; 19/04/2018 – Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse® in MuSK Antibody Positive Myasthenia Gravis; 14/03/2018 – Catalyst Pharmaceuticals 4Q Adj Loss/Shr 5c; 29/05/2018 – CPRX FIRDAPSE GETS FDA PRIORITY REVIEW STATUS; 29/05/2018 – CATALYST PHARMACEUTICALS REPORTS FIRDAPSE PDUFA DATE NOV. 28; 02/05/2018 – Catalyst Pharmaceuticals to Hold First Quarter Financial Results and Corporate Update Conference Call and Webcast on Thursday,

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Institutional Positions Chart